# Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

> **NCT06518837** · PHASE2 · RECRUITING · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 40 (estimated)

## Conditions studied

- Hormone Receptor-Positive Breast Cancer
- HER2-Negative Breast Cancer

## Interventions

- **DRUG:** Tirzepatide

## Key facts

- **NCT ID:** NCT06518837
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06518837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06518837, "Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06518837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*